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Drug-eluting stents (DES) are commonly used for coronary artery disease and patients with DES require
antiplatelet therapy because of the risk of late stent thrombosis. Accordingly problems can occur in the
perioperative period due to late thrombosis of a stent after discontinuation of antiplatlet therapy before
surgery. A 64-year-old man was diagnosed as having a right renal tumor (T1aN0M0) and his performance
status was 4. Three years earlier, a DES had been placed in a coronary artery and he was taking aspirin plus
ticlopidine. These drugs were stopped at 7 days before surgery and we started heparin (15,000 U/day).
Heparin was continued during and after radical nephrectomy. Although operative blood loss was only 178
ml, the amount of bleeding within 5 hours after surgery was 1,620 ml. The wound was re-opened, but there
was no obvious bleeding source, so oozing from the muscle was controlled. His blood pressure dropped and
cardiac arrest occurred at 22 hours after re-operation, but he was resuscitated with blood transfusion and the
bleeding stopped after the dose of heparin was reduced. Three days after the operation, antiplatelet therapy
was re-started and heparin was ceased at 10 days after surgery. The blood clot in the right retroperitoneal
space formed an abscess at 28 days after radical nephrectomy. After drainage, the retroperitoneal space was
washed twice a day for about 40 days. The wound healed, and he currently has no evidence of recurrence
or metastasis and has no cardiac sequelae.
(Hinyokika Kiyo 56 : 265-268, 2010)
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緒 言
冠動脈インターベンション後に留置する冠動脈金属









































右腎下極に 4×3.5 cm の腫瘍を指摘された (Fig. 1）．


















time (ACT) を指標とし，ACT 200秒前後を目標にコ
ントロールする，○3術中もヘパリンを○2と同様の目標
値で投与コントロールする，○4最も短時間の術式を選






ACT は140秒，APTT は70秒と ACT は目標値に達し
ていなかった．
2007年 5月16日全身麻酔下に経腰的右腎摘出術を施














数回にわたり収縮期血圧が 80 mmHg 以下へ低下し，








Fig. 1. Computed tomography (CT) showed a mass
(4.0×3.5 cm) with early enhancement in the
right kidney.
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Fig. 2. Clinical courses.
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心臓学会 (The American Heart Assocoation : AHA) およ
び関連諸学会は DES 使用に関する緊急勧告を2007年
2 月に行い，DES 留置後の 2 剤併用血小板薬療法
（アスピリンとチエノピリジン系薬物の使用）の投与
期間を短縮しないように強く勧告している8)．この勧
告では DES 留置後12カ月は 2剤併用血小板療法が強
く推奨されているが中止可能時期については言及され
ておらず，現在もコンセンサスはえられていない．待




ican College of Cardiology (ACC) と AHA による非心
臓手術に対する周術期心血管評価と管理ガイドライ
ン｣12) では，○1 DES 留置例の場合365日以上あけてア
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